Cargando…
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
BACKGROUND: Birth outcome data with dolutegravir exposure during pregnancy, particularly in the first trimester, are needed. SETTING: Data were prospectively collected from the Antiretroviral Pregnancy Registry and European Pregnancy and Paediatric HIV Cohort Collaboration. METHODS: We reviewed 2 la...
Autores principales: | Vannappagari, Vani, Thorne, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905407/ https://www.ncbi.nlm.nih.gov/pubmed/30939532 http://dx.doi.org/10.1097/QAI.0000000000002035 |
Ejemplares similares
-
74. Maternal Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: The Antiretroviral Pregnancy Registry (APR)
por: Vannappagari, Vani, et al.
Publicado: (2021) -
Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020) -
Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry
por: Vannappagari, V, et al.
Publicado: (2015) -
Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017) -
2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)